uniQure plunges 65% as 48-month Huntington’s gene therapy data misses key stat
uniQure (NASDAQ: QURE) shares dropped 64% after 48-month data for its Huntington’s disease treatment, AMT-130, missed statistical significance on a primary measure. The company attributed this to survivor bias. Despite the setback, the FDA’s regulatory filing is based on 36-month data, which showed significant results. The treatment demonstrated a manageable safety profile and dose-dependent efficacy.
How this was made
The 30-second read
Why it matters
The 48‑month miss undermines confidence in the trial’s robustness, prompting a sharp sell‑off despite strong 36‑month results.
Market read
The news explains the massive intra‑day price decline and highlights potential spill‑over to similar biotech stocks.
What to watch
Regulatory filing relies on 36‑month data, which remains highly significant.
Background
uniQure is a Nasdaq‑listed gene‑therapy developer pursuing accelerated approval for Huntington’s disease.
Ticker impact
48‑month Huntington’s disease trial missed statistical significance, causing a 64% share drop.
likely continued pressure as investors price in the statistical miss.
The primary endpoint failure is a material new fact; market reaction was immediate and large.
Market effects
Biotech sector may see broader risk aversion to late‑stage gene‑therapy trials.
US biotech stocks could face heightened volatility.
Limited to gene‑therapy investors; no immediate macro effect.
Counterpoint
Post‑hoc analysis restored significance; some may view the data as still supportive.
Key entities
- companyuniQure N.V.
Gene‑therapy developer (NASDAQ: QURE).
